Progenics Pharmaceuticals (PGNX) Shares are Down -9.01%

Progenics Pharmaceuticals (PGNX) : During the past 4 weeks, traders have been relatively bearish on Progenics Pharmaceuticals (PGNX), hence the stock is down -4.97% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -9.46% relative to the S&P 500. The 4-week change in the price of the stock is -5.1% and the stock has fallen -9.01% in the past 1 week.

The stock has recorded a 20-day Moving Average of 10.06% and the 50-Day Moving Average is 2.6%.The 200 Day SMA reached 14.58%. Progenics Pharmaceuticals, Inc. is up 21.14% in the last 3-month period. Year-to-Date the stock performance stands at -2.77%.


Progenics Pharmaceuticals (NASDAQ:PGNX): The stock opened in the green at $6.15 on Friday, but the bulls found it difficult to push the prices higher. The stock reached a high of $6.19 and a low of $5.94 for the day. The stock did not find buyers even at the lows and closed at $5.96 recording a loss of -2.93%. 957,479 shares exchanged hands during the trading day. The stock had closed at $6.14 in the previous days trading.

Progenics Pharmaceuticals, engaged in developing medicines for oncology. The Company completed Phase II clinical trials of two product candidates for prostate cancer, and resumed a pivotal Phase II trial of an ultra-orphan radiotherapy candidate for pheochromocytoma. Its principal clinical-stage product candidates in oncology are PSMA ADC, 1404 (trofolastat) and Azedra. PSMA ADC is a human monoclonal antibody-drug conjugate designed to deliver a chemotherapeutic agent to cancer cells by targeting the three-dimensional structure of the PSMA protein. 1404 (trofolastat) is a radio-labeled small molecule, which binds PSMA and acts as an imaging agent to diagnose and detect prostate cancer. Azedra is a radiotherapeutic product candidate in development as a treatment for pheochromocytoma, a rare tumor found in the adrenal glands, and related paraganglioma tumors occurring in other tissues. The Company also commercializes Relistor, a cure for opioid-induced constipation (OIC).

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.